Latest News and Press Releases

KØBENHAVN, Danmark, 5. marts 2025 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...

COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding...

De reviderede resultater bekræfter en omsætning for helåret på DKK 5.716 mio. og et resultat af primær drift før afskrivninger og nedskrivninger (EBITDA) på DKK 1.603 mio.To nye tidlig-fase...

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced. ...

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 –...

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 –...

Aftale om kontraktproduktion er første skridt i nyt samarbejde om at etablere kapacitet med henblik på at udvide tilgængeligheden af chikungunyavaccinen i lav- og mellemindkomstlande. KØBENHAVN,...

Contract manufacturing agreement marks the first step in collaboration to establish supply for expanded access to chikungunya vaccines in low- and middle-income countries. COPENHAGEN, Denmark,...

Første chikungunyavaccine som er godkendt til personer helt ned til 12 år, hvilket imødekommer et uopfyldt behov for forebyggelse af chikungunya hos yngre rejsende.Forventet kommerciel lancering i...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the...